Bipolar II disorder
Methodology & AI Transparency ⓘ
Bipolar II disorder Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Under Depression, Bipolar & Mood Disorders diagnostic criteria (F31.81), workup for Bipolar II disorder integrates sleep-wake rhythm assessment [Bipolar II disorder F31.81] with evidence-graded therapy tailored to PHQ-9 Symptom Severity in Bipolar II disorder (F31.81: Score) response.
- 2 Real-world patient consensus: Federal ICD-10-CM code F31.81 categorizes Bipolar II disorder under Depression, Bipolar & Mood Disorders.
- 3 Typical cash cost range: Workup highlights for Bipolar II disorder (F31.81): sleep-wake rhythm assessment [Bipolar II disorder F31.81].
- 4 Top reported side effects / signs: Follow-up benchmark in Bipolar II disorder: maintaining PHQ-9 Symptom Severity in Bipolar II disorder (F31.81: Score) within < 4 (clinical remission) (F31.81).
Ask our AI Specialists anything about Bipolar II disorder
What Is Bipolar II disorder?
Under Depression, Bipolar & Mood Disorders diagnostic criteria (F31.81), workup for Bipolar II disorder integrates sleep-wake rhythm assessment [Bipolar II disorder F31.81] with evidence-graded therapy tailored to PHQ-9 Symptom Severity in Bipolar II disorder (F31.81: Score) response.
Pathophysiology, Underlying Causes & Clinical Presentation
Underlying Bipolar II disorder (code F31.81) is dopamine) signaling imbalance [Bipolar II disorder F31.81], which Depression, Bipolar & Mood Disorders clinicians address while surveilling PHQ-9 Symptom Severity in Bipolar II disorder (F31.81: Score) (< 4 (clinical remission) (F31.81)).
Common Symptoms & Clinical Signs
- • Presentation of Bipolar II disorder (F31.81): loss of interest in Bipolar II disorder (F31.81: or pleasure in)
- • Secondary Bipolar II disorder clinical sign: persistent low mood, in Bipolar II disorder (F31.81: emotional flatness, or)
- • Symptom flares in Bipolar II disorder correlating with PHQ-9 Symptom Severity in Bipolar II disorder (F31.81: Score) deviation outside < 4 (clinical remission) (F31.81)
- • Functional depression & mood impact requiring sleep-wake rhythm assessment [Bipolar II disorder F31.81] evaluation (F31.81)
Bipolar II disorder Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | F31.81 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Depression, Bipolar & Mood Disorders | NLM Clinical Tables |
| Diagnostic / Lab Marker: PHQ-9 Symptom Severity in Bipolar II disorder (F31.81: Score) | < 4 (clinical remission) (F31.81) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: TSH & Free in Bipolar II disorder (F31.81: T4 Rule-Out) | TSH 0.8 – 2.5 mIU/L (F31.81) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Serum Vitamin D in Bipolar II disorder (F31.81: & RBC Folate) | 25(OH)D 40 – 65 ng/mL (F31.81) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Bipolar II disorder
Treatment selection for Bipolar II disorder depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Bipolar II disorder)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Modeling the efficacy of a novel antidepressant zuranolone for: What a 8,735-Participant Study Found Primary side effects related to zuranolone included somnolence, headache, dizziness, and sedation, with no severe safety signals observed. Journal of affective disorders • 2026-01-01 • Meta-Analysis | N = 8,735 | 99/100 | PMID 40876640 ↗ |
| New Insights on Treatment of SSRI-resistant: What a 1,496-Participant Study Found These results suggest a modest yet statistically significant advantage in full symptom relief rates when switching patients with SSRI-resistant depression to a non-SSRI rather than an SSRI antidepressant. Biological psychiatry • 2008-04-01 • Meta-Analysis | N = 1,496 | 94/100 | PMID 17919460 ↗ |
| New Insights on Efficacy of Lumateperone in Patients With Bipolar Depression With Mixed: What a 376-Participant Study Found Conclusions: Lumateperone 42 mg significantly improved symptoms of depression and disease severity in patients with an MDE associated with bipolar I or bipolar II disorder, with or without mixed features. The Journal of clinical psychiatry • 2023-04-24 • Phase III Randomized Trial | N = 376 | 93/100 | PMID 37103915 ↗ |
| Can This Approach Help? Inside the Latest Research on Duration of Adjunctive Antidepressant Maintenance in Bipolar I In a trial involving patients with bipolar I disorder and a recently remitted depressive episode, adjunctive treatment with escitalopram or bupropion XL that continued for 52 weeks did not show a significant benefit as... The New England journal of medicine • 2023-08-03 • Randomized Controlled Trial | N = 90 | 88/100 | PMID 37530824 ↗ |
| Can This Approach Help? Inside the Latest Research on Benefits and safety of Lumateperone for Major Depressive Episodes Associated With Lumateperone at 42 mg/day significantly improved depression symptoms and was generally well tolerated in patients with major depressive episodes associated with both bipolar I and bipolar II disorders. The American journal of psychiatry • 2021-12-15 • Phase III Randomized Trial | N = 188 | 88/100 | PMID 34551584 ↗ |
Bipolar II disorder Patient Community & “People Like Me” Threads
Filter Bipolar II disorder community threads and patient logs by age, biological sex, dosage, and treatment duration.